GLPwatch
Papers (10378)
Page 96 of 173, ranked by citation count.
- Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
- Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy.
- Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
- Lipidized Prolactin-Releasing Peptide Agonist Attenuates Hypothermia-Induced Tau Hyperphosphorylation in Neurons.
- Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.
- Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
- A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
- Medicines for long-term obesity management.
- Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database.
- Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis
- Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study.
- Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.
- Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
- Tirzepatide as an Insulin Sensitizer.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
- GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice.
- The Use of Semaglutide in Patients Undergoing Lumbar Fusion Does not Increase 90-Day Medical or 1-Year Implant Complications.
- Liraglutide protects Rin-m5f β cells by reducing procoagulant tissue factor activity and apoptosis prompted by microparticles under conditions mimicking Instant Blood-Mediated Inflammatory Reaction.
- Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
- Optimizing management of glycaemia.
- High price and demand for semaglutide means lack of access for US patients.
- GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair.
- Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch<sup>®</sup> among self-injection-naïve patients with type 2 diabetes mellitus in Japan.
- Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.
- A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
- Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
- Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
- The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
- Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
- The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.
- [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
- Switching from insulin to liraglutide improved glycemic control and the quality of life scores in a case of type 2 diabetes and active Crohn's disease.
- Weight Recidivism After Bariatric Surgery: A Narrative Review.
- Semaglutide enhances PINK1/Parkin‑dependent mitophagy in hypoxia/reoxygenation‑induced cardiomyocyte injury.
- [Liraglutide promotes proliferation and migration of cardiac microvascular endothelial cells through PI3K/Akt and MAPK/ERK signaling pathways].
- Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States.
- Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.
- Weight Loss Therapies and Hypertension Benefits.
- Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics.
- Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro.
- Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.
- Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.
- A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.
- SAD-A Promotes Glucose-Stimulated Insulin Secretion Through Phosphorylation and Inhibition of GDIα in Male Islet β Cells.
- Exendin-4 exhibits a tumour suppressor effect in SKOVR-3 and OVACR-3 ovarian cancer cells lines by the activation of SIRT1 and inhibition of NF-κB.
- Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.
- Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
- Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.
- Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion.
- Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
- Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy.
- Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats.
- Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.
- Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.
- Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
- Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.
- Weight loss medication prescription prevalence in the active component, 2018-2023.
- Tirzepatide-associated starvation ketoacidosis.